Alprolix label?

What does the Alprolix label say it’s for?

Alprolix (coagulation factor IX [recombinant], albumin fusion protein) is indicated for treatment and control of bleeding episodes and perioperative management of bleeding in patients with hemophilia B (congenital factor IX deficiency) 1.

It is also used for routine prophylaxis to reduce the frequency of bleeding episodes in people with hemophilia B 1.

How does the label describe dosing and how is it given?

The label provides individualized dosing instructions based on the patient’s type of hemophilia, treatment goal (treatment of bleeding vs prophylaxis), and the factor IX level response needed. Alprolix is given as an intravenous infusion 1.

What important safety information is on the label?

The Alprolix prescribing information includes warnings and precautions that typically cover:
- Hypersensitivity reactions
- Inhibitor development (formation of factor IX inhibitors that can reduce effectiveness)
- Risks related to thrombosis in certain circumstances

Those warnings and detailed contraindications/precautions are spelled out in the full U.S. prescribing information 1.

What can patients expect regarding monitoring?

The label emphasizes monitoring for:
- Factor IX activity responses to guide dosing
- Development of inhibitors, especially if bleeding is not controlled as expected

It also includes guidance for clinical assessment during treatment 1.

Where to find the exact “label” document (U.S. prescribing information)?

You can view or download the official Alprolix prescribing information here via DrugPatentWatch.com: DrugPatentWatch – Alprolix label/prescribing information.

---

Sources